Practical approach to statin intolerance

Česká verzia

Authors: Tomáš Štulc; Šárka Beránková; Richard Češka
Authors place of work: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2015; 61(11): 936-941
Category: Reviews

Summary

Statins significantly decrease the cardiovascular risk and the reduction of cholesterol by statins has become a milestone in the prevention of cardiovascular diseases for a large group of patients. In spite of that an adequate use of statins in many patients is limited by adverse symptoms which lead to interruption of the therapy in some patients and low adherence to the therapy in others. Therefore the subject of statin intolerance is of great clinical importance. Statin intolerance can be defined as an incidence of myalgia or other adverse symptoms associated with a statin therapy, which lead to its interruption. Nonetheless, even if such symptoms develop during the statin therapy, these adverse effects are frequently not associated with the treatment and most patients with an anamnesis suggesting episodes of such symptoms are able to tolerate an adequate statin therapy. It is therefore of great clinical importance to identify the actual cases of statin intolerance in order to avoid the unnecessary interruption of the statin therapy in the patients who would benefit from it. Regarding patients with a proven statin intolerance, statins should be administered according to an altered scheme and if tolerated, the dose should be gradually increased until the highest tolerated level is reached. When this careful approach is followed, most patients are able to tolerate some level of statin therapy at least. Besides that, there may be also other lipid-reducing drugs needed to reach the required goals. If the achievement of the lipid target values is difficult, a rigorous control of the risk factors may help in reducing the cardiovascular risk.

Key words:
myalgia – low-dose statin therapy – statin intolerance – statins – side effects on statins

Zdroje

1. Baigent C, Blackwell L, Emberson J et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681.

2. 2 Wei MY, Ito MK, Cohen JD et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013; 7(5): 472–483.

3. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19(6): 403–414.

4. Parker BA, Capizzi JA, Grimaldi AS et al. Effect of statins on skeletal muscle function. Circulation 2013; 127(1): 96–103.

5. Guyton JR, Bays HE, Grundy SM et al. The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014; 8(3 Suppl): S72-S81.

6. Rosenson RS, Baker SK, Jacobson TA et al. The National Lipid Association‘s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8(3 Suppl): S58-S71.

7. Cornier MA, Eckel RH. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? Curr Atheroscler Rep 2015; 17(2): 475.

8. Bays H, Cohen DE, Chalasani N et al. The National Lipid Association‘s Statin Safety Task Force.An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8(3 Suppl): S47-S57.

9. Rojas-Fernandez CH, Goldstein LB, Levey AI et al. The National Lipid Association‘s Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 2014; 8(3 Suppl): S5-S16.

10. Stulc T, Ceska R. Statins, glycemia, and diabetes mellitus: another point of view. Curr Atheroscler Rep 2014; 16(12): 458.

11. Stroes ES, Thompson PD, Corsini A et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36(17): 1012–1022.

12. Mancini GB, Tashakkor AY, Baker S et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29(12): 1553–1568.

13. Pirillo A, Catapano AL. Statin intolerance: diagnosis and remedies. Curr Cardiol Rep 2015; 17(5): 27.

14. Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience. JAMA 2015; 313(10): 1011–1012.

15. Preiss D, Sattar N. Classification of reported statin intolerance. Curr Opin Lipidol 2015; 26(1): 65–66.

16. Banach M, Rizzo M, Toth PP et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23.

17. Zhang H, Plutzky J, Skentzos S et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158(7): 526–534.

18. Mampuya WM, Frid D, Rocco M et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013; 166(3): 597–603.

19. Robison CD, Bair TL, Horne BD et al. Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol 2014; 8(4): 401–407.

20. Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositismyalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses 2011; 77(4): 658–661.

21. Taylor BA, Lorson L, White CM et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015; 238(2): 329–335.

22. Banach M, Serban C, Sahebkar A et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015; 90(1): 24–34.

23. Backes JM, Moriarty PM, Ruisinger JF et al. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007; 100(3): 554–555.

24. Ruisinger JF, Backes JM, Gibson CA et al. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009; 103(3): 393–394.

25. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008; 101(12): 1747–1748.

26. Honkanen M. Managing the statin-intolerant patient: low-dose/low-frequency treatment regimens. LipidSpin 2013; 11(4): 9–12. Dostupné z WWW: <https://www.lipid.org/communications/lipid_spin/lipid-spin-fall-2013>. Accessed June 1, 2015.

27. Cannon CP et al. IMPROVE IT Invesgtigators. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after actue coronary syndromes. Presented at: American heart Association Scientific Sessions: Late-braking clinical trials: Anti-Lipid Therapy and Prevention of CAD, November 17, 2014. Dostupné z WWW:<http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469598.pdf>. Accessed June 1, 2015.

28. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375(9729):1875–1884.

29. HPS2-THRIVE Collaborative Group. Landray MJ, Haynes R, Hopewell JC et al. Effects of extended release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371(3): 203–212.

30. AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365(24): 2255–2267.

31. Sabatine MS, Giugliano RP, Wiviott SD et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1500–1509.

32. Robinson JG, Farnier M, Krempf M et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients. ESC Congress 2014. Hot Line session: Coronary artery disease and lipids, 31 August 2014. Dostupné z WWW: <http://www.escardio.org/Congresses-&-Events/Congress-resources/ESC-Congress-365/Long-term-safety-tolerability-and-efficacy-of-alirocumab-versus-placebo-in-high>.